Search research articles
Contact Us
Filters
Showing results (21-30 of 31) with videos related to
Page
of 4
Sort By:
Cell
|
July 30, 2019
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility
Jane Guan, Wei Zhou, Marc Hafner, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 23, 2021
Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer
Jason R Zbieg, Jun Liang, Jun Li, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)
|
March 2, 2018
Conjugation of Indoles to Antibodies through a Novel Self-Immolating Linker
Peter S Dragovich, Robert A Blake, Chunjiao Chen, et al.
Chemmedchem
|
November 2, 2019
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
Thomas H Pillow, Pragya Adhikari, Robert A Blake, et al.
Journal of Medicinal Chemistry
|
February 17, 2021
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties
Peter S Dragovich, Thomas H Pillow, Robert A Blake, et al.
Journal of Medicinal Chemistry
|
February 17, 2021
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy
Peter S Dragovich, Thomas H Pillow, Robert A Blake, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 7, 2020
Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
Peter S Dragovich, Pragya Adhikari, Robert A Blake, et al.
Nature
|
October 19, 2017
USP7 small-molecule inhibitors interfere with ubiquitin binding
Lorna Kategaya, Paola Di Lello, Lionel Rougé, et al.
Elife
|
July 14, 2016
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
James D Joseph, Beatrice Darimont, Wei Zhou, et al.
Elife
|
January 8, 2019
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
James D Joseph, Beatrice Darimont, Wei Zhou, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 31) with videos related to
Sort By:
Page
of 4
Cell
|
July 30, 2019
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility
Jane Guan, Wei Zhou, Marc Hafner, et al.
Bioorganic & Medicinal Chemistry Letters
|
August 23, 2021
Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer
Jason R Zbieg, Jun Liang, Jun Li, et al.
Chemistry (Weinheim an Der Bergstrasse, Germany)
|
March 2, 2018
Conjugation of Indoles to Antibodies through a Novel Self-Immolating Linker
Peter S Dragovich, Robert A Blake, Chunjiao Chen, et al.
Chemmedchem
|
November 2, 2019
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
Thomas H Pillow, Pragya Adhikari, Robert A Blake, et al.
Journal of Medicinal Chemistry
|
February 17, 2021
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 1: Exploration of Antibody Linker, Payload Loading, and Payload Molecular Properties
Peter S Dragovich, Thomas H Pillow, Robert A Blake, et al.
Journal of Medicinal Chemistry
|
February 17, 2021
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy
Peter S Dragovich, Thomas H Pillow, Robert A Blake, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 7, 2020
Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα)
Peter S Dragovich, Pragya Adhikari, Robert A Blake, et al.
Nature
|
October 19, 2017
USP7 small-molecule inhibitors interfere with ubiquitin binding
Lorna Kategaya, Paola Di Lello, Lionel Rougé, et al.
Elife
|
July 14, 2016
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
James D Joseph, Beatrice Darimont, Wei Zhou, et al.
Elife
|
January 8, 2019
Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
James D Joseph, Beatrice Darimont, Wei Zhou, et al.
Page
of 4